

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

Information for the public

Published: 3 March 2021

www.nice.org.uk

Lenalidomide (Revlimid) is available on the NHS as a possible maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults. It is only recommended at a dose of 10 mg daily on days 1 to 21 of a 28-day treatment cycle.

If you are not eligible for lenalidomide but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Myeloma UK](#), 0800 980 3332
- [Blood Cancer UK](#), 0808 169 5155
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 00 00.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4032-5